Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Schwabe

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
JCI Insight|May 8, 2020
Development of an RNAi therapeutic for alpha-1-antitrypsin liver diseaseChristine I Wooddell, Keith Blomenkamp, Ryan M Peterson, et al.
Hepatology Communications|October 4, 2022
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis BMan-Fung Yuen, Elina Berliba, Wattana Sukeepaisarnjaroen, et al.
Journal of Hepatology|December 13, 2022
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitisLung-Yi Mak, Ed Gane, Christian Schwabe, et al.
Journal of Hepatology|July 23, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBMan-Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.
Clinical Therapeutics|April 29, 2018
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3Wendy W Yeh, Iain P Fraser, Patricia Jumes, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
JCI Insight|May 8, 2020
Development of an RNAi therapeutic for alpha-1-antitrypsin liver diseaseChristine I Wooddell, Keith Blomenkamp, Ryan M Peterson, et al.
Hepatology Communications|October 4, 2022
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis BMan-Fung Yuen, Elina Berliba, Wattana Sukeepaisarnjaroen, et al.
Journal of Hepatology|December 13, 2022
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitisLung-Yi Mak, Ed Gane, Christian Schwabe, et al.
Journal of Hepatology|July 23, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBMan-Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.
Clinical Therapeutics|April 29, 2018
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3Wendy W Yeh, Iain P Fraser, Patricia Jumes, et al.
Pageof 6